Mark L. Jacobson sold $5.2M of AXSM
Chief Operating Officer at Axsome Therapeutics, Inc.. 45,783 shares at an average of $114.48, traded Sep 16, 2025, filed Sep 17, 2025.
Score components
- +20RoleCOO
- +25Trade size$5.2M at market
- +20Share of holdings soldSold 100% of holdings
- +15Cluster4 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001193125-25-206494, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Sep 16, 2025 | SOpen-market sale Common Stock10b5-1 | -5,783 | $116.19 | $672k | 0 | Sep 17, 2025 |
| Sep 16, 2025 | MOption exercise Common Stock10b5-1 | +25,000 | $4.95 | $124k | 25,000 | Sep 17, 2025 |
| Sep 16, 2025 | MOption exercise Common Stock10b5-1 | +15,000 | $4.85 | $73k | 40,000 | Sep 17, 2025 |
| Sep 16, 2025 | SOpen-market sale Common Stock10b5-1 | -40,000 | $114.23 | $4.6M | 0 | Sep 17, 2025 |
| Sep 16, 2025 | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -25,000 | $0.00 | $0 | 0 | Sep 17, 2025 |
| Sep 16, 2025 | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -15,000 | $0.00 | $0 | 0 | Sep 17, 2025 |
Related signals
Other insiders at Axsome Therapeutics, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 30Weak | Axsome Therapeutics, Inc. | Mark L. Jacobson Chief Operating Officer | $2.1M 10,000 shares | -100% | |
| 38Weak | Axsome Therapeutics, Inc. | Mark L. Jacobson Chief Operating Officer | $1.2M 10,000 shares | -100% | |
| 50Moderate | Axsome Therapeutics, Inc. | Herriot Tabuteau Chief Executive Officer | $7.4M 62,880 shares | -179% | |
| 27Weak | AXSMbuy Axsome Therapeutics, Inc. | Mark Coleman director | $200k 1,575 shares | +3% | |
| 30Weak | Axsome Therapeutics, Inc. | Mark E Saad director | $1.1M 9,127 shares | -48% | |
| 40Moderate | Axsome Therapeutics, Inc. | Roger Jeffs director | $1.7M 13,464 shares | -19% | |
| 38Weak | Axsome Therapeutics, Inc. | Roger Jeffs director | $7.3M 60,000 shares | -46% | |
| 33Weak | Axsome Therapeutics, Inc. | Roger Jeffs director | $4.4M 36,694 shares | -22% | |
| 33Weak | Axsome Therapeutics, Inc. | Hunter R. Murdock General Counsel | $1.4M 13,514 shares | -180% | |
| 33Weak | Axsome Therapeutics, Inc. | Hunter R. Murdock General Counsel | $2.3M 22,500 shares | -300% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.